LQDA (Liquidia Corp) Net Profit

Corporate emblem and logo of liquidia.com (LQDA)

An asset-light model with outsourced production provides operational flexibility for Liquidia Corporation (LQDA), as confirmed by the company's profit chart. The value of 0.14 represents the most recent level of this metric. Stable demand for lifelong lung therapy creates a foundation for growth, although prolonged patent disputes and the battle for market share in the inhalation segment create significant commercial risks.

LQDA (Liquidia) Company Net Income history from 07/04/2022 to 10/31/2026

Financial and market metric breakdowns for Liquidia (LQDA)

- price and consensus price forecast:
Stock Quotes Liquidia Inc.|LQDA - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization Liquidia Inc.|LQDA - Real Price to Acquire Entire Company
- book capitalization data:
Accounting Value of a Share Liquidia|LQDA - Company Book Value|Market-to-Book Ratio liquidia.com|LQDA - Cumulative Company Assets
- debt and solvency information:
Aggregate Debt to Capital Liquidia Corporation|LQDA - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital Liquidia Corp|LQDA - Company Aggregate Debts|Debts to Book Value Liquidia Inc.|LQDA - Company Long-Term Debt|Company Short-Term Loans and Borrowings Liquidia|Quick Liquidity liquidia.com
- net income and valuation multiples indicators:
LQDA - Net Profit
Fundamental valuation:LQDA Liquidia Inc.
Flagship merchandise of Liquidia Corp

This indicator measures the net financial return per share, transforming quarterly data into a continuous daily sequence to eliminate information gaps. The current value of 0.14 in the net income metric reflects the actual business resilience of Liquidia Corporation (LQDA) amid patent disputes and FDA regulatory risks associated with a high dependency on a single drug.

Main competitors

Net Income Haleon Corp|KVUE (Kenvue Inc.) - Net Profit|Net Profit veronapharma.com|Net Income MENS (Jyong Biotech)|LGND (Ligand Pharmaceuticals Incorporated) - Final Profit|Company Net Income Amneal Pharmaceuticals Inc AMRX|Perrigo Corp (PRGO) - Company Net Income|ALVO: Net Income|glpg.com - Profit After Payment of Taxes|ANIP: Net Profit|MannKind Corp - Final Profit|AMPH (Amphastar) - Net Profit|Company Net Income Pacira Corp PCRX|Company Net Income ARS Pharmaceuticals (SPRY)|TBPH (theravance.com) - Final Profit|Company Net Income Aquestive Therapeutics, Inc. AQST|scPharmaceuticals, Inc. - Company Net Income|Tectonic - Net Profit|Net Financial Result Tonix Pharmaceuticals Holding TNXP|sxtchina.com (SXTC) - Company Net Income|Annual Net Income Eupraxia Pharmaceuticals Inc. EPRX|Net Income BHST|Net Profit Invizyne Technologies|Net Profit ORMP|Net Financial Result enterabio.com|Net Profit HYFT (MindWalk Holdings)|ABVC: Company Profit|Cumberland Pharmaceuticals Inc. - Net Profit|Net Financial Result Quantum BioPharma Ltd. QNTM|FGEN: Net Profit|Telomir Pharmaceuticals Corp (TELO) - Net Profit|Net Income RANI|SNYR: Final Profit|Net Profit RLYB|Net Income lexariabioscience.com LEXX|Company Net Income Pulmatrix Corp PULM|Pheton Holdings Limited (PTHL) - Company Net Income|APM - Company Net Income|Final Profit LYRA (lyratherapeutics.com)|Impact BioMedical Inc (IBO) - Company Net Income|Profit After Tax TNFA (TNF Pharmaceuticals, Inc.)|Company Net Income cbdMD Inc.|Company Net Income PainReform Corp PRFX|Company Net Income Altamira Therapeutics (CYTO)|LIPO (lipella.com) - Final Profit|Net Profit OPTN (OptiNose)|Net Profit Pieris Pharmaceuticals Inc PIRS|PROC: Net Income|Petros Pharma - Profit After Payment of Taxes|QLI: Net Profit|SLRN - Net Financial Result|Company Net Income TFF Pharmaceuticals, Inc.